Medinice S.A.

Warsaw Stock Exchange ICE.WA

Medinice S.A. Return on Equity (ROE) for the year ending December 31, 2023: -15.29%

Medinice S.A. Return on Equity (ROE) is -15.29% for the year ending December 31, 2023, a -9.06% change year over year. Return on equity measures profit against shareholder equity; higher ROE indicates superior profitability and value creation.

Medinice S.A. Return on Equity (ROE) for the year ending December 31, 2022 was -14.02%, a -99.02% change year over year.
Medinice S.A. Return on Equity (ROE) for the year ending December 31, 2021 was -7.05%, a 62.11% change year over year.
Medinice S.A. Return on Equity (ROE) for the year ending December 31, 2020 was -18.59%, a 31.91% change year over year.
Medinice S.A. Return on Equity (ROE) for the year ending December 31, 2019 was -27.31%, a 51.85% change year over year.

Key data

Date	Return on Equity (ROE)	Return on Capital Employed (ROCE)	Interest Coverage Ratio	Debt to Equity Ratio

Warsaw Stock Exchange: ICE.WA

Medinice S.A.

CEO	Mr. Sanjeev Choudhary
IPO Date	Sept. 1, 2018
Location	Poland
Headquarters	ul. Chmielna 132/134
Employees	16
Sector	Healthcare
Industries Medical Instruments 3D Printing Biotechnology Clinical Trials Pharmaceuticals

Description

Medinice S.A. provides medical solution for cardiology and cardiac surgery. The company support scientists for product commercialization including prototyping, clinical trials and certification, and product sales. Medinice S.A. was founded in 2012 and is based in Warsaw, Poland.

Key trends

Past 5 years